Well it has been about a year and this one finally got great news today:
AOLS Aeolus Receives Orphan Drug Designation From US FDA for AEOL 10150 for Treatment of Idiopathic Pulmonary Fibrosis
"Orphan Drug Designation entitles the sponsor to a seven-year marketing exclusivity period, clinical protocol assistance with the FDA, as well as federal grants and tax credits."
Keep this one on your list. They have a phase one cancer trial coming up for the effects of radiation on the lungs. Lots of good stuff ahead here.